About US
Contact us
-
Roche may want Alexion, but is the price right?Roche may have the wherewithal to bid for Alexion and an appetite for the company's rare-disease drugs. But it might not have the stomach for the price. Roche ($RHHBY) is reportedly scouting for fina2013/7/16
-
Novartis CEO Jimenez says China is a difficult market, but worth itChinais a huge market and offers huge potential for pharma. But it is an increasingly challenging place to do business for Western drugmakers, as GlaxoSmithKline's ($GSK) run-in with authorities over2013/7/15
-
Telegraph: Sources say 30 GSK employees under house arrestChina-watchers think probes part of effort to divert attention away from domestic shortcomings Reports are starting to put a few details around what is going on with more than two dozen GlaxoSmithKli2013/7/15
-
Chinese authorities say GSK employees confess to briberyLast month GSK fired R&D chief in China for alleged misconduct GlaxoSmithKline ($GSK) has for weeks been saying that it could find no evidence to confirm allegations that any of its employees inC2013/7/12
-
BMS, Pfizer say FDA to review Eliquis for new useThe FDA will considerEliquisfor a new indication, one which Pfizer ($PFE) and partner Bristol-Myers Squibb ($BMY) hope can help the blood thinner hit the sales potential analysts predicted for the dru2013/7/12
-
Pharma, FDA still lagging in post-marketing safety researchThe good news: Drugmakers are wrapping up more post-marketing safety studies, now that the FDA can crack the whip. More good news: Companies got to work on a bigger proportion of the studies required.2013/7/11
-
Risperdal plaintiff's lawyer demands sealed J&J docs from FDAIf you don't succeed in court, try the FDA. That's the approach of a Philadelphia lawyer who wants to make someRisperdaldata public, but is barred from doing so by a federal judge's order. As thePhil2013/7/11
-
Data fraud allegedly delayed FDA nod for Pfizer-BMS drug EliquisData errors and alleged fraud at clinical trial sites in China held up approval of Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) clot-fighting drugEliquis, according to media reports. The allegation2013/7/10
-
Vivus hooks up with Menarini to hawk ED pill Spedra in $121M dealIf you've been following the Vivus ($VVUS) proxy fight, you know the company's lack of marketing muscle has been a big point of contention. Proxy challengerFirst Manhattanhas aired its grievances loud2013/7/10
-
Vivus, FMC both tout proxy advisers' support for board nomineesIf Vivus shareholders were looking for some unqualified advice for their proxy votes, they're disappointed. Proxy advisers have now weighed in on the fight for control at Vivus, and the counsel is a m2013/7/9